MA71363A - L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose - Google Patents

L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose

Info

Publication number
MA71363A
MA71363A MA71363A MA71363A MA71363A MA 71363 A MA71363 A MA 71363A MA 71363 A MA71363 A MA 71363A MA 71363 A MA71363 A MA 71363A MA 71363 A MA71363 A MA 71363A
Authority
MA
Morocco
Prior art keywords
oxaborole
dihydrobenzo
trifluoromethyl
glucose
hydroxy
Prior art date
Application number
MA71363A
Other languages
English (en)
French (fr)
Inventor
Mikael Kofod-Hansen
Henning THØGERSEN
Thomas Kruse
Per Sauerberg
Carsten Behrens
Vojtech BALSÁNEK
Zuzana DROBNÁKOVÁ
Miroslav HAVRÁNEK
Vladislav KOTEK
Milan STENGL
Ivan Snajdr
Hana VÁNOVÁ
Thomas HØEG-JENSEN
Martin Werner Borchsenius MÜNZEL
Jakob Ewald Rasmussen
Ladislav Droz
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of MA71363A publication Critical patent/MA71363A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q3/00—Condition responsive control processes
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/10—Methods of screening libraries by measuring physical properties, e.g. mass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA71363A 2017-11-09 2018-11-08 L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose MA71363A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17200734 2017-11-09
EP18178294 2018-06-18
EP23172873.4A EP4227313B1 (en) 2017-11-09 2018-11-08 1-hydroxy-4-(trifluoromethyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylic acid and its use in the synthesis of glucose-sensitive albumin-binding derivatives

Publications (1)

Publication Number Publication Date
MA71363A true MA71363A (fr) 2025-04-30

Family

ID=64049277

Family Applications (2)

Application Number Title Priority Date Filing Date
MA71363A MA71363A (fr) 2017-11-09 2018-11-08 L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose
MA050552A MA50552A (fr) 2017-11-09 2018-11-08 Dérivés de liaison à l'albumine sensibles au glucose

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050552A MA50552A (fr) 2017-11-09 2018-11-08 Dérivés de liaison à l'albumine sensibles au glucose

Country Status (7)

Country Link
US (4) US11186595B2 (https=)
EP (2) EP4227313B1 (https=)
JP (3) JP7254792B2 (https=)
CN (2) CN111315751B (https=)
ES (2) ES3056386T3 (https=)
MA (2) MA71363A (https=)
WO (1) WO2019092125A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
WO2019092125A1 (en) * 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
EP3946363A2 (en) * 2019-03-29 2022-02-09 Novo Nordisk A/S Glucose sensitive insulin derivatives
CN112174989B (zh) * 2019-07-02 2023-06-20 江西同和药业股份有限公司 一种克立硼罗的制备方法
JP7834341B2 (ja) * 2019-07-31 2026-03-24 シーエス ファーマシューティカルズ エルエルシー グルコース調節型立体配座スイッチを有するインスリン類似体
EP4126058A1 (en) * 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
JP2024500284A (ja) * 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
EP4255468A4 (en) * 2020-12-02 2024-06-05 The Regents of University of California INJECTABLE BIODEGRADABLE POLYMER COMPLEX FOR GLUCOSE-DEPENDENT INSULIN DELIVERY
WO2022235691A1 (en) * 2021-05-03 2022-11-10 The Trustees Of Indiana University Molecular design of glucose sensors in glucose-responsive insulin analogues
CN114478597B (zh) * 2021-12-29 2023-08-29 宁波大学 一种快速识别葡萄糖手性的试剂及其制备方法和应用
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
AU2024251658A1 (en) * 2023-04-11 2025-09-18 Protomer Technologies, Inc. Compounds containing one or more diboronates and related insulin analogs
AU2024295902A1 (en) 2023-07-18 2026-01-15 Novo Nordisk A/S Pharmaceutical compositions of insulin derivatives

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU628674B2 (en) 1989-10-19 1992-09-17 Nippon Oil And Fats Company, Limited Polymer complexes of a sugar response type
AU2001263775A1 (en) 2000-06-02 2001-12-11 Novo-Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
US7316999B2 (en) * 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
EP1453860A2 (en) 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7317000B2 (en) 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
AU2003223930A1 (en) 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
DE102008052314A1 (de) * 2008-10-15 2010-04-22 Syntatec Chemicals Gmbh Aromatische und heteroaromatische Poly-trifluoroborate und Verfahren zur Herstellung
WO2011000823A1 (en) 2009-06-30 2011-01-06 Novo Nordisk A/S Insulin derivatives
TWI458732B (zh) * 2012-06-27 2014-11-01 國立交通大學 具硼酸基團連接子及含有其之生物感測元件
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2015097276A1 (en) * 2013-12-23 2015-07-02 Syngenta Participations Ag Benzoxaborole fungicides
WO2015106292A1 (en) * 2014-01-13 2015-07-16 Coferon, Inc. Bcr-abl tyrosine-kinase ligands capable of dimerizing in an aqueous solution, and methods of using same
AR103397A1 (es) * 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
JP6914844B2 (ja) 2015-03-13 2021-08-04 ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎ Ｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ グルコース制御立体配座スイッチを含むインスリン類似体
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
UA121354C2 (uk) * 2016-05-12 2020-05-12 Анакор Фармасутікалз, Інк. Нові сполуки для лікування паразитарних захворювань
US10690675B2 (en) * 2017-04-14 2020-06-23 Georgia Tech Research Corporation Methods for enriching glycopeptides for global analysis of glycoproteins
WO2019092125A1 (en) * 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
EP3781147A4 (en) 2018-04-16 2022-04-20 University of Utah Research Foundation Glucose-responsive insulin

Also Published As

Publication number Publication date
EP4227313C0 (en) 2025-10-22
US20220081451A1 (en) 2022-03-17
US11186595B2 (en) 2021-11-30
EP3707145A1 (en) 2020-09-16
JP2021502372A (ja) 2021-01-28
EP4227313A1 (en) 2023-08-16
CN117624207A (zh) 2024-03-01
MA50552A (fr) 2020-09-16
ES3056386T3 (en) 2026-02-20
CN111315751B (zh) 2023-12-12
JP7254792B2 (ja) 2023-04-10
US20230331745A1 (en) 2023-10-19
CN111315751A (zh) 2020-06-19
US20250122226A1 (en) 2025-04-17
US20200325160A1 (en) 2020-10-15
US11767332B2 (en) 2023-09-26
JP2023080126A (ja) 2023-06-08
EP4227313B1 (en) 2025-10-22
EP3707145B1 (en) 2023-06-21
US12227528B2 (en) 2025-02-18
ES2956032T3 (es) 2023-12-12
JP2025061325A (ja) 2025-04-10
EP3707145C0 (en) 2023-06-21
JP7622123B2 (ja) 2025-01-27
WO2019092125A1 (en) 2019-05-16

Similar Documents

Publication Publication Date Title
MA71363A (fr) L'acide 1-hydroxy-4-(trifluorométhyl)-1,3-dihydrobenzo[c] [1,2]oxaborole-6-carboxylique et son utilisation dans la synthèse de dérivés de liaison à l'albumine sensibles au glucose
EP3416547A4 (en) ASSESSMENT OF BLOOD FLOW AND TISSUE BLOODING BY FLUORESCENT-MEDIATED PHOTOPLETHYSMOGRAPHY
AR105854A1 (es) Parche para monitorear la salud
EP2911754A4 (en) MEDICAL LEG ARRANGEMENT FOR INCREASING THE MOVEMENT AREA OF A LEG TO SUPPORT HEALING AND TO STRENGTHEN DAMAGED, INJURED AND / OR REPLACED BONES, MUSCLES AND / OR WOVEN LEGS
RU2010129238A (ru) Применение производных изотиоцианата в качестве противомиеломных средств
EP4044943A4 (en) ATHERECTOMY CATHETER WITH A MOLDABLE DISTAL TIP
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
EP2114377A4 (en) CONTROLLED RELEASE OF ACTIVE SUBSTANCES IN THE SKIN
BRPI0922686A2 (pt) associação de licopeno, polifenol e vitaminas para o cuidado das matérias queratínicas
EP3823525A4 (en) PERFUSION AND OXYGEN ENCOURAGEMENT MEASUREMENT
EP4225402C0 (en) Blood draw syringe with hemolysis protection
DK3749308T3 (da) Behandling af patienter med klassisk fabrys sygdom med migalastat
EP1845911A4 (en) COMPONENT FOR FACILITATING THE FASTENING OF A STOMA BAND TO THE SKIN
IL282375A (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders
WO2017105565A3 (en) Compositions for therapeutics, targeted pet imaging and methods of their use
EP3768836A4 (en) ANIMAL MODEL FOR ALZHEIMER'S MORBUS AND ITS USE
GT200900319A (es) (oxazolidinon-5-il-metil)-2-tiofen-carboxamidas sustituidas y su uso en el campo de la coagulación sanguínea
EP3533862A4 (en) METHYLOCYSTIS AND USE THEREOF IN THE SELECTIVE SOLUTION AND PREPARATION OF (S) -ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETATE
MA52617A (fr) Biomarqueurs sanguins de l'accident vasculaire cérébral
MA50266A (fr) Procédés de prévention de l'oxydation de la méthionine dans des immunoconjugués
EP3610848A4 (en) SKIN CLEANSING COMPOSITION
EP3662907A4 (en) ANTI-AGING OR SKIN REGENERATIVE COMPOSITION WITH PIPERONYLIC ACID AS THE ACTIVE INGREDIENT
EP3731800A4 (en) BODY CARE PRODUCTS AND PROCEDURES WITH TRANS-1-CHLORINE-3,3,3-TRIFLUOROPROPENE
EP3610850A4 (en) SKIN CLEANSING COMPOSITION
HUE055904T2 (hu) 2-([1,2,3]triazol-2-il)-benzoesav-származékok elõállítása